{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:05:53Z","timestamp":1790701553698,"version":"4.1.0"},"reference-count":148,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","award":["RGP.02\/725\/46"],"award-info":[{"award-number":["RGP.02\/725\/46"]}],"id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.retram.2026.103604","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:42:27Z","timestamp":1785368547000},"page":"103604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Harnessing dendritic cells (DCs) for melanoma immunotherapy: From basic biology to clinical strategies"],"prefix":"10.1016","volume":"74","author":[{"given":"Donisha Sonal","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaa Ibrahim","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali G.","family":"Alkhathami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Kareem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirzagaleb","family":"Tillyashaykhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa Abbas","family":"Al-Khafaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhair I.","family":"Al-Mashhadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesam R.","family":"Kadhum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami Najaf","family":"Bokhoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser Fakri","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2026.103604_bib0001","doi-asserted-by":"crossref","first-page":"127","DOI":"10.12788\/j.sder.2018.028","article-title":"Immunotherapy for melanoma","volume":"37","author":"Cuevas","year":"2018","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.retram.2026.103604_bib0002","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2394252","article-title":"Immunotherapy and delivery systems for melanoma","volume":"20","author":"Liu","year":"2024","journal-title":"Hum Vaccin ImmunOther"},{"key":"10.1016\/j.retram.2026.103604_bib0003","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1200\/JCO.22.02575","article-title":"Neoadjuvant checkpoint immunotherapy and melanoma: the time is now","volume":"41","author":"Long","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.retram.2026.103604_bib0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11864-019-0607-8","article-title":"Targeted therapy and immunotherapy for melanoma in Japan","volume":"20","author":"Namikawa","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.retram.2026.103604_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9235638","article-title":"Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions","volume":"2020","author":"Ralli","year":"2020","journal-title":"J Immunol Res"},{"key":"10.1016\/j.retram.2026.103604_bib0006","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.soc.2019.02.001","article-title":"Current immunotherapy practices in Melanoma","volume":"28","author":"Rothermel","year":"2019","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.retram.2026.103604_bib0007","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1038\/s41467-023-42881-4","article-title":"Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients","volume":"14","author":"Adamik","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.retram.2026.103604_bib0008","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41467-024-45358-0","article-title":"Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: the MIND-DC randomized phase III trial","volume":"15","author":"Bol","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.retram.2026.103604_bib0009","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2217\/fon.16.13","article-title":"Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20\/eltrapuldencel-T)","volume":"12","author":"Javed","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.retram.2026.103604_bib0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jconrel.2022.11.053","article-title":"Dendritic cell derived exosomes loaded neoantigens for personalized cancer immunotherapies","volume":"353","author":"Li","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.retram.2026.103604_bib0011","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1080\/21645515.2016.1197453","article-title":"Dendritic cell vaccination in melanoma patients: from promising results to future perspectives","volume":"12","author":"Boudewijns","year":"2016","journal-title":"Hum Vaccin ImmunOther"},{"key":"10.1016\/j.retram.2026.103604_bib0012","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/CMR.0000000000000356","article-title":"Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience","volume":"27","author":"de Rosa","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.retram.2026.103604_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1755-148X.2008.00535.x","article-title":"Dendritic cells and melanoma therapy","volume":"22","author":"Goding","year":"2009","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.retram.2026.103604_bib0014","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/pcmr.12496","article-title":"The melanoma field with dendritic roots","volume":"29","author":"Aplin","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.retram.2026.103604_bib0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12976-015-0007-0","article-title":"Enhancing dendritic cell immunotherapy for melanoma using a simple mathematical model","volume":"12","author":"Castillo-Montiel","year":"2015","journal-title":"Theor Biol Med Model"},{"key":"10.1016\/j.retram.2026.103604_bib0016","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1080\/21645515.2019.1680239","article-title":"Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine","volume":"16","author":"Dillman","year":"2020","journal-title":"Hum Vaccin ImmunOther"},{"key":"10.1016\/j.retram.2026.103604_bib0017","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00008390-200504000-00003","article-title":"Cytokine expression and dendritic cell density in melanoma sentinel nodes","volume":"15","author":"Botella-Estrada","year":"2005","journal-title":"Melanoma Res"},{"key":"10.1016\/j.retram.2026.103604_bib0018","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S1470-2045(06)70678-7","article-title":"Dendritic-cell vaccination for metastatic melanoma?","volume":"7","author":"Chen","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.retram.2026.103604_bib0019","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/CMR.0b013e32834b58fa","article-title":"Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome","volume":"21","author":"Ridolfi","year":"2011","journal-title":"Melanoma Res"},{"key":"10.1016\/j.retram.2026.103604_bib0020","first-page":"1","article-title":"Dendritic cell subsets and locations","volume":"348","author":"Balan","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.retram.2026.103604_bib0021","first-page":"163","article-title":"Dendritic cell-based immunotherapy","volume":"276","author":"Berger","year":"2003","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0022","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.semcdb.2018.02.015","article-title":"Dendritic cells as cancer therapeutics","volume":"86","author":"Bryant","year":"2019","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.retram.2026.103604_bib0023","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1158\/2767-9764.CRC-22-0022","article-title":"Comprehensive characterization of the multiple myeloma immune microenvironment using integrated scRNA-seq, CyTOF, and CITE-seq analysis","volume":"2","author":"Yao","year":"2022","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.retram.2026.103604_bib0024","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/jleuko\/qiae164","article-title":"EP2\/EP4 targeting prevents tumor-derived PGE2-mediated immunosuppression in cDC2s","volume":"116","author":"Cuenca-Escalona","year":"2024","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.retram.2026.103604_bib0025","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9775736","article-title":"A machine learning workflow of multiplexed immunofluorescence images to interrogate activator and tolerogenic profiles of conventional type 1 dendritic cells infiltrating melanomas of disease-free and metastatic patients","volume":"2022","author":"De Le\u00f3n Rodr\u00edguez","year":"2022","journal-title":"J Oncol"},{"key":"10.1016\/j.retram.2026.103604_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1209588","article-title":"Nuanced role for dendritic cell intrinsic IRE1 RNase in the regulation of antitumor adaptive immunity","volume":"14","author":"Flores-Santiba\u00f1ez","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0027","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/2326-6066.CIR-22-0494","article-title":"Inhibitor of apoptosis proteins antagonist induces T-cell proliferation after cross-presentation by dendritic cells","volume":"11","author":"Hoefsmit","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.retram.2026.103604_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001963","article-title":"Human CD141(+) dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model","volume":"9","author":"Lee","year":"2021","journal-title":"J ImmunOther Cancer"},{"key":"10.1016\/j.retram.2026.103604_bib0029","article-title":"The natural killer-dendritic cell immune axis in anti-cancer immunity and immunotherapy","volume":"11","author":"Peterson","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0030","article-title":"Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potential","volume":"5","author":"Becker","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.retram.2026.103604_bib0031","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2015113","article-title":"Immunological responses to adjuvant vaccination with combined CD1c(+) myeloid and plasmacytoid dendritic cells in stage III melanoma patients","volume":"11","author":"Bloemendal","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.retram.2026.103604_bib0032","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/jid.2014.29","article-title":"Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3","volume":"134","author":"Camisaschi","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.retram.2026.103604_bib0033","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/jid.2010.24","article-title":"Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor","volume":"130","author":"Charles","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.retram.2026.103604_bib0034","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12967-014-0376-x","article-title":"Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma","volume":"13","author":"Chevolet","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.retram.2026.103604_bib0035","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/pcmr.12371","article-title":"Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma","volume":"28","author":"Lad\u00e1nyi","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.retram.2026.103604_bib0036","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00430-020-00680-4","article-title":"Molecular mechanisms of dendritic cell migration in immunity and cancer","volume":"209","author":"de Winde","year":"2020","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0037","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.3390\/ijms24044253","article-title":"Dendritic cell and cancer therapy","volume":"24","author":"Galati","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.retram.2026.103604_bib0038","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.critrevonc.2007.03.002","article-title":"Aging and the dendritic cell system: implications for cancer","volume":"64","author":"Shurin","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.retram.2026.103604_bib0039","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1586\/1744666X.2015.987663","article-title":"Dendritic cell-based vaccine research against cancer","volume":"11","author":"Mody","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41568-024-00787-3","article-title":"Dendritic cell maturation in cancer","volume":"25","author":"Moon","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.retram.2026.103604_bib0041","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/eji.200636499","article-title":"Both Langerhans cells and interstitial DC cross-present melanoma antigens and efficiently activate antigen-specific CTL","volume":"37","author":"Cao","year":"2007","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0042","article-title":"Langerhans cells as morphologic mimickers of Atypical melanocytes on reflectance confocal microscopy: a case report and review of the literature","volume":"11","author":"Chuchvara","year":"2021","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.retram.2026.103604_bib0043","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.3390\/jpm12122072","article-title":"Langerhans cells-revising their role in skin pathologies","volume":"12","author":"Neagu","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.retram.2026.103604_bib0044","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.3390\/ijms23073441","article-title":"Tolerogenic IDO1(+)CD83(-) langerhans cells in sentinel lymph nodes of patients with melanoma","volume":"23","author":"Gerlini","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.retram.2026.103604_bib0045","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202451020","article-title":"Langerhans cells orchestrate apoptosis of DNA-damaged keratinocytes upon high-dose UVB skin exposure","volume":"54","author":"Ortner","year":"2024","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0046","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3389\/fimmu.2017.01594","article-title":"Strategies to improve the efficacy of dendritic cell-based immunotherapy for melanoma","volume":"8","author":"Hargadon","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0047","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fimmu.2013.00192","article-title":"Tumor-altered dendritic cell function: implications for anti-tumor immunity","volume":"4","author":"Hargadon","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0048","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.4049\/jimmunol.170.7.3488","article-title":"Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis","volume":"170","author":"P\u00e9guet-Navarro","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0049","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1158\/0008-5472.CAN-12-4115","article-title":"Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms","volume":"73","author":"Mao","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.retram.2026.103604_bib0050","doi-asserted-by":"crossref","DOI":"10.3390\/cells10082136","article-title":"The role of glycosylation in melanoma progression","volume":"10","author":"De Vellis","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.retram.2026.103604_bib0051","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nri.2018.3","article-title":"The tumour glyco-code as a novel immune checkpoint for immunotherapy","volume":"18","author":"Rodr\u00cdguez","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1040600","article-title":"Unique CLR expression patterns on circulating and tumor-infiltrating DC subsets correlated with clinical outcome in melanoma patients","volume":"13","author":"Sosa Cuevas","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1120434","article-title":"The melanoma tumor glyco-code impacts human dendritic cells' functionality and dictates clinical outcomes","volume":"14","author":"Sosa Cuevas","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0054","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fimmu.2014.00024","article-title":"Metabolic influences that regulate dendritic cell function in tumors","volume":"5","author":"Dong","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0055","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.3390\/cancers12082085","article-title":"Plasmacytoid dendritic cell impairment in metastatic melanoma by lactic acidosis","volume":"12","author":"Monti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.retram.2026.103604_bib0056","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1158\/0008-5472.CAN-13-3583","article-title":"Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment","volume":"74","author":"Cekic","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.retram.2026.103604_bib0057","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.retram.2026.103604_bib0058","article-title":"In vivo dendritic cell reprogramming for cancer immunotherapy","volume":"386","author":"Ascic","year":"2024","journal-title":"Science (1979)"},{"key":"10.1016\/j.retram.2026.103604_bib0059","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s12094-018-1987-0","article-title":"Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy","volume":"21","author":"Bloemendal","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.retram.2026.103604_bib0060","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-12-2583","article-title":"Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients","volume":"73","author":"Tel","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.retram.2026.103604_bib0061","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1158\/1078-0432.CCR-15-2205","article-title":"Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells","volume":"22","author":"Schreibelt","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.retram.2026.103604_bib0062","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s12967-025-06403-8","article-title":"Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial","volume":"23","author":"Bulgarelli","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.retram.2026.103604_bib0063","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.3389\/fimmu.2019.02353","article-title":"Dendritic cell vaccination in metastatic melanoma turns \"non-T cell inflamed\" into \"T-cell inflamed\" tumors","volume":"10","author":"Bulgarelli","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0064","first-page":"803","article-title":"Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science (1979)"},{"key":"10.1016\/j.retram.2026.103604_bib0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/CMR.0000000000000058","article-title":"MicroRNAs and dendritic cell-based vaccination in melanoma patients","volume":"24","author":"de Rosa","year":"2014","journal-title":"Melanoma Res"},{"key":"10.1016\/j.retram.2026.103604_bib0066","article-title":"Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III\/IV melanoma patients: results of a phase I\/IIa trial","volume":"41","author":"Van Decar","year":"2024","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.retram.2026.103604_bib0067","first-page":"14","article-title":"TLR agonist rHP-NAP as an adjuvant of dendritic cell-based vaccine to enhance anti-melanoma response","volume":"17","author":"Hou","year":"2020","journal-title":"Iran J Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0068","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00262-018-2207-z","article-title":"Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma","volume":"67","author":"Gargett","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0069","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s12967-025-06403-8","article-title":"Adjuvant dendritic cell-based immunotherapy in melanoma: insights into immune cell dynamics and clinical evidence from a phase II trial","volume":"23","author":"Bulgarelli","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.retram.2026.103604_bib0070","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003675","article-title":"Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma","volume":"9","author":"Storkus","year":"2021","journal-title":"J ImmunOther Cancer"},{"key":"10.1016\/j.retram.2026.103604_bib0071","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1080\/21645515.2019.1680239","article-title":"Genomic, proteomic, and immunologic associations with a durable complete remission of measurable metastatic melanoma induced by a patient-specific dendritic cell vaccine","volume":"16","author":"Dillman","year":"2020","journal-title":"Hum Vaccin ImmunOther"},{"key":"10.1016\/j.retram.2026.103604_bib0072","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/cgt.2011.13","article-title":"Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma","volume":"18","author":"Yang","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.retram.2026.103604_bib0073","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/CMR.0000000000000342","article-title":"Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma","volume":"27","author":"Fukuda","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.retram.2026.103604_bib0074","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1158\/1078-0432.CCR-11-1261","article-title":"Route of administration modulates the induction of dendritic cell vaccine\u2013induced antigen-specific T cells in advanced melanoma patients","volume":"17","author":"Lesterhuis","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.retram.2026.103604_bib0075","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3892\/or.2012.1956","article-title":"Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial","volume":"28","author":"Oshita","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.retram.2026.103604_bib0076","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00262-022-03272-8","article-title":"Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial","volume":"72","author":"Adams","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0077","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jconrel.2023.01.034","article-title":"Liposomal celecoxib combined with dendritic cell therapy enhances antitumor efficacy in melanoma","volume":"354","author":"Jahani","year":"2023","journal-title":"J Controlled Release"},{"key":"10.1016\/j.retram.2026.103604_bib0078","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/CMR.0000000000000356","article-title":"Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience","volume":"27","author":"de Rosa","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.retram.2026.103604_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtbi.2023.111489","article-title":"Treatment of melanoma with dendritic cell vaccines and immune checkpoint inhibitors: a mathematical modeling study","volume":"568","author":"Xue","year":"2023","journal-title":"J Theor Biol"},{"key":"10.1016\/j.retram.2026.103604_bib0080","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1479-5876-11-148","article-title":"Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model","volume":"11","author":"Tan","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.retram.2026.103604_bib0081","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/imt-2017-0114","article-title":"Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine","volume":"10","author":"Hardin","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.retram.2026.103604_bib0082","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/01.cji.0000211309.90621.8b","article-title":"Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity","volume":"29","author":"Palucka","year":"2006","journal-title":"J Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0083","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/eji.200425847","article-title":"A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3. DP4-peptide-pulsed dendritic cells","volume":"35","author":"Zhang","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0084","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/CJI.0b013e31817fd90b","article-title":"Phase ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma","volume":"31","author":"Redman","year":"2008","journal-title":"J Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0085","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000474","article-title":"Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells","volume":"8","author":"Zhou","year":"2020","journal-title":"J ImmunOther Cancer"},{"key":"10.1016\/j.retram.2026.103604_bib0086","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00262-009-0813-5","article-title":"Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity","volume":"59","author":"Matsushita","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0087","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00262-014-1558-3","article-title":"Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula","volume":"63","author":"Van Lint","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110376","article-title":"Neudesin regulates dendritic cell function and antitumor CD8+ T cell immunity","volume":"268","author":"Masuda","year":"2024","journal-title":"Clin Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0089","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00262-015-1743-z","article-title":"Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine","volume":"64","author":"Pizzurro","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002449","article-title":"Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma","volume":"9","author":"Saberian","year":"2021","journal-title":"J ImmunOther Cancer"},{"key":"10.1016\/j.retram.2026.103604_bib0091","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1586\/14760584.2.6.825","article-title":"Dendritic cell vaccination and immunostimulation in advanced melanoma","volume":"2","author":"Ridolfi","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.retram.2026.103604_bib0092","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000329","article-title":"TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma","volume":"8","author":"De Keersmaecker","year":"2020","journal-title":"J ImmunOther Cancer"},{"key":"10.1016\/j.retram.2026.103604_bib0093","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/2326-6066.CIR-24-0333","article-title":"First-in-Human clinical trial of vaccination with WDVAX, a dendritic cell\u2013Activating scaffold incorporating autologous tumor cell lysate, in patients with metastatic melanoma","volume":"13","author":"Hodi","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.retram.2026.103604_bib0094","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2249.2005.02700.x","article-title":"Mature dendritic cells differentiated in the presence of interferon-b and interleukin-3 prime functional antigen-specific CD8+ T cells","volume":"139","author":"Renneson","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0095","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1158\/1078-0432.CCR-09-1254","article-title":"Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma","volume":"15","author":"Ribas","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.retram.2026.103604_bib0096","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ymthe.2023.06.005","article-title":"An iPSC-derived exosome-pulsed dendritic cell vaccine boosts antitumor immunity in melanoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.retram.2026.103604_bib0097","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2217\/fon.16.13","article-title":"Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20\/eltrapuldencel-T)","volume":"12","author":"Javed","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.retram.2026.103604_bib0098","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/CJI.0000000000000212","article-title":"Anti-IL-10\u2013mediated enhancement of antitumor efficacy of a dendritic cell\u2013targeting MIP3\u03b1-gp100 vaccine in the B16F10 mouse melanoma model is dependent on type I interferons","volume":"41","author":"Gordy","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0099","first-page":"803","article-title":"A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science (1979)"},{"key":"10.1016\/j.retram.2026.103604_bib0100","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/CJI.0b013e31821dcb31","article-title":"Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma","volume":"34","author":"Wilgenhof","year":"2011","journal-title":"J Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0101","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4067\/S0716-97602013000400014","article-title":"TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer","volume":"46","author":"Salazar-Onfray","year":"2013","journal-title":"Biol Res"},{"key":"10.1016\/j.retram.2026.103604_bib0102","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00002371-200309000-00006","article-title":"Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma","volume":"26","author":"Palucka","year":"2003","journal-title":"J Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0103","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2249.2005.02948.x","article-title":"Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients","volume":"142","author":"Escobar","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0104","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bbrc.2011.08.089","article-title":"CD4 T cell dependent tumor immunity stimulated by dendritic cell based vaccine","volume":"413","author":"Zhang","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.retram.2026.103604_bib0105","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide-or tumorlysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.retram.2026.103604_bib0106","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/504979","article-title":"Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis","volume":"2010","author":"Ridolfi","year":"2010","journal-title":"J Immunol Res"},{"key":"10.1016\/j.retram.2026.103604_bib0107","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.18632\/oncotarget.13736","article-title":"IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination","volume":"8","author":"Llopiz","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.retram.2026.103604_bib0108","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20032118","article-title":"Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells","volume":"199","author":"Paczesny","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.retram.2026.103604_bib0109","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/0008-5472.CAN-05-3396","article-title":"Immunization of stage IV melanoma patients with Melan-A\/MART-1 and gp100 peptides plus IFN-\u03b1 results in the activation of specific CD8+ T cells and monocyte\/dendritic cell precursors","volume":"66","author":"Di Pucchio","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.retram.2026.103604_bib0110","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1038\/s41467-023-42881-4","article-title":"Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients","volume":"14","author":"Adamik","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.retram.2026.103604_bib0111","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1738812","article-title":"An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial","volume":"9","author":"Charles","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.retram.2026.103604_bib0112","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.3389\/fimmu.2019.02353","article-title":"Dendritic cell vaccination in metastatic melanoma turns \u201cnon-T cell inflamed\u201d into \u201cT-cell inflamed\u201d tumors","volume":"10","author":"Bulgarelli","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0113","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/CMR.0000000000000758","article-title":"Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma","volume":"31","author":"Adams","year":"2021","journal-title":"Melanoma Res"},{"key":"10.1016\/j.retram.2026.103604_bib0114","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3982942","article-title":"Proteomic identification of heat shock-induced danger signals in a melanoma cell lysate used in dendritic cell-based cancer immunotherapy","volume":"2018","author":"Gonz\u00e1lez","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.retram.2026.103604_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136911","article-title":"Prophylactic dendritic cell-based vaccines efficiently inhibit metastases in murine metastatic melanoma","volume":"10","author":"Markov","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.retram.2026.103604_bib0116","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00002371-200001000-00008","article-title":"Generation of T-cell immunity to a murine melanoma using MART-1\u2013engineered dendritic cells","volume":"23","author":"Ribas","year":"2000","journal-title":"J Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0117","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/gt.2011.1","article-title":"Phase I\/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma","volume":"18","author":"Steele","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.retram.2026.103604_bib0118","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1002\/ijc.21679","article-title":"Induction of strong and persistent MelanA\/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients","volume":"118","author":"Tuettenberg","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.retram.2026.103604_bib0119","first-page":"101","volume":"01","author":"Tripathi","year":"2019"},{"key":"10.1016\/j.retram.2026.103604_bib0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1248\/bpbreports.6.5_155","article-title":"Neudesin, a secretory protein, suppresses cytokine production in bone marrow-derived dendritic cells stimulated by lipopolysaccharide","volume":"6","author":"Kondo","year":"2023","journal-title":"BPB Reports"},{"key":"10.1016\/j.retram.2026.103604_bib0121","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1479-5876-8-89","article-title":"Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma","volume":"8","author":"Ribas","year":"2010","journal-title":"J Transl Med"},{"key":"10.1016\/j.retram.2026.103604_bib0122","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1479-5876-6-6","volume":"6","author":"von Euw","year":"2008","journal-title":"J Transl Med"},{"key":"10.1016\/j.retram.2026.103604_bib0123","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1920739","article-title":"Activity-regulated cytoskeleton-associated protein\/activity-regulated gene 3.1 (Arc\/Arg3. 1) enhances dendritic cell vaccination in experimental melanoma","volume":"10","author":"Zhang","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.retram.2026.103604_bib0124","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00262-002-0318-y","article-title":"Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen","volume":"52","author":"Smithers","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0125","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2015113","article-title":"Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients","volume":"11","author":"Bloemendal","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.retram.2026.103604_bib0126","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jconrel.2018.01.004","article-title":"Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma","volume":"272","author":"Zhu","year":"2018","journal-title":"J Controlled Release"},{"key":"10.1016\/j.retram.2026.103604_bib0127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2022.12.011","article-title":"Investigating silver nanoparticles and resiquimod as a local melanoma treatment","volume":"183","author":"Tambunlertchai","year":"2023","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.retram.2026.103604_bib0128","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00262-016-1809-6","article-title":"A phase I\/IIa clinical trial in stage IV melanoma of an autologous tumor\u2013dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2","volume":"65","author":"Greene","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-012-1295-4","article-title":"High lipid content of irradiated human melanoma cells does not affect cytokine-matured dendritic cell function","volume":"62","author":"Pizzurro","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s002620050504","article-title":"Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma","volume":"47","author":"Chakraborty","year":"1998","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0131","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/1078-0432.CCR-13-3017","article-title":"Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma","volume":"20","author":"Chodon","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.retram.2026.103604_bib0132","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1039\/D3BM00702B","article-title":"In vivo targeting of a tumor-antigen encoded DNA vaccine to dendritic cells in combination with tumor-selective chemotherapy eradicates established mouse melanoma","volume":"11","author":"Barui","year":"2023","journal-title":"Biomater Sci"},{"key":"10.1016\/j.retram.2026.103604_bib0133","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ajo.2014.07.014","article-title":"Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients","volume":"158","author":"Bol","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.retram.2026.103604_bib0134","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.ophtha.2016.06.027","article-title":"Adjuvant dendritic cell vaccination in high-risk uveal melanoma","volume":"123","author":"Bol","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.retram.2026.103604_bib0135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1749-0774.2003.tb00151.x","article-title":"Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives","volume":"16","author":"Morisaki","year":"2003","journal-title":"Hum Cell"},{"key":"10.1016\/j.retram.2026.103604_bib0136","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.785231","article-title":"A one-armed phase I dose escalation trial design: personalized vaccination with ikk\u03b2-matured, RNA-loaded dendritic cells for metastatic uveal melanoma","volume":"13","author":"Koch","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0137","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109966","article-title":"Interferon-\u03b12b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines","volume":"125","author":"Sheng","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.retram.2026.103604_bib0138","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00262-010-0925-y","article-title":"Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival","volume":"60","author":"Cornforth","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0139","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.biomaterials.2016.10.047","article-title":"Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine","volume":"113","author":"Shi","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.retram.2026.103604_bib0140","first-page":"145","article-title":"Imiquimod combined with dendritic cell vaccine decreases treg proportion and enhances anti-tumor responses in mice bearing melanoma. Xi bao yu fen zi mian yi xue za zhi=","volume":"33","author":"Ren","year":"2017","journal-title":"Chin J Cell Mol Immunol"},{"key":"10.1016\/j.retram.2026.103604_bib0141","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40425-018-0330-1","article-title":"Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses","volume":"6","author":"Dillman","year":"2018","journal-title":"J ImmunOther Cancer"},{"key":"10.1016\/j.retram.2026.103604_bib0142","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s12094-018-1987-0","article-title":"Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy","volume":"21","author":"Bloemendal","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.retram.2026.103604_bib0143","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1200\/JCO.2003.04.042","article-title":"Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients","volume":"21","author":"Bedrosian","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.retram.2026.103604_bib0144","first-page":"407","article-title":"Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines","volume":"26","author":"Dillman","year":"2011","journal-title":"Cancer BiOther Radiopharm"},{"key":"10.1016\/j.retram.2026.103604_bib0145","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s00262-012-1268-7","article-title":"Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients","volume":"61","author":"Tittarelli","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.retram.2026.103604_bib0146","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/cells15020099","article-title":"Advances in mRNA-based melanoma vaccines: a narrative review of lipid nanoparticle and dendritic cell delivery platforms","volume":"15","author":"Sisk","year":"2026","journal-title":"Cells"},{"key":"10.1016\/j.retram.2026.103604_bib0147","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/13543784.2021.1896702","article-title":"Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy","volume":"30","author":"Supabphol","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.retram.2026.103604_bib0148","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.3390\/cancers15082206","article-title":"Dendritic cell subsets in melanoma: pathophysiology, clinical prognosis and therapeutic exploitation","volume":"15","author":"Sosa Cuevas","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:31:08Z","timestamp":1790699468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318626000401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":148,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2452318626000401"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2026.103604","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing dendritic cells (DCs) for melanoma immunotherapy: From basic biology to clinical strategies","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2026.103604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103604"}}